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HIGHLIGHTS
•	 In England, human papillomavirus (HPV) testing is planned to replace cytological screening by 2019.
•	 HPV testing is likely to decrease cervical cancer incidence and costs.
•	 HPV testing may lead to more colposcopies and this may be mitigated with a longer screening interval.
AbSTrACT
Objectives In England, human papillomavirus (HPV) 
testing is to replace cytological screening by 2019–2020. 
We conducted a model-based economic evaluation 
to project the long-term clinical impact and cost-
effectiveness of routine cytology versus HPV testing.
Methods An individual-based model of HPV acquisition, 
natural history, and cervical cancer screening was used 
to compare cytological screening and HPV testing with 
cytology triage for women aged 25–64 years (with either 
3- or 5-year screening intervals for women aged under 
50 years). The model was fitted to data from England's 
National Health Service Cervical Screening Programme. 
Both clinical and economic outcomes were projected to 
inform cost-effectiveness analyses.
results HPV testing is likely to decrease annual cytology 
testing (by 2.76 million), cervical cancer incidence (by 290 
cases), and health system costs (by £13 million). It may 
increase the number of colposcopies, although this could 
be reduced without leading to more cancers compared 
with primary cytology by increasing the interval between 
screens to 5 years. The impact in terms of quality-adjusted 
life-years (QALYs) depends on the quality of life weight 
given to colposcopies versus cancer.
Conclusions England's move from cytology to HPV 
screening may potentially be life-saving and cost-effective. 
Cost-effectiveness can be improved further by extending 
the interval between screens or using alternative triage 
methods such as partial or full genotyping.
InTrOduCTIOn
Persistent infection with a high-risk type of human 
papillomavirus (HPV) is a risk for cervical cancer. 
In England, as elsewhere, secondary prevention of 
cervical cancer has been based on cytological testing 
to detect cervical abnormalities since the introduc-
tion of the National Health Service Cervical Screening 
Programme (NHSCSP) in 1988. The incidence of new 
diagnoses of cervical cancer per 100 000 females 
(based on the 2013 European Standard Population) 
has fallen from 12.1 in 1995 to 9.4 in 2016. Currently, 
women aged 25–49 and 50–64 years receive invita-
tions for screening every 3 and 5 years, respectively. 
Additionally, 12–13-year-old girls have been vacci-
nated against HPV since 2008, with coverage of the 
two-dose schedule above 80%.1
The development of rapid and sensitive tests for 
HPV now offers an alternative screening for cervical 
cancer. European trials of HPV testing as a primary 
cervical screening suggest that it provides 60%–70% 
greater protection against cervical cancer compared 
with cytology.2 Testing for high-risk HPV to determine 
management of women with borderline or low-grade 
abnormalities, and as a test-of-cure for recently 
treated women, has been used in England since 2011. 
In 2013, a pilot study of implementing screening in 
which the primary assessment is an HPV test was 
initiated at several sites across England. The National 
Screening Committee has agreed to replace cytolog-
ical testing with HPV testing as the primary means 
of assessment England-wide by 2019, following a 
review of evidence including cost-effectiveness.3
HPV testing has higher sensitivity for high-grade 
lesion detection and provides stronger negative predic-
tive power than cytology,4 leading to the possibility of 
extending the screening interval following a nega-
tive HPV test. Additionally, concern that primary HPV 
screening may lead to over-referral to colposcopy in 
young women, in whom there is a high prevalence of 
HPV infection, has led to discussions surrounding the 
introduction of additional triage tests prior to colposcopy.
To address these questions around the introduction 
of primary HPV testing in England, we conducted a 
model-based evaluation of the clinical impact and 
cost-effectiveness of switching from cytology to HPV 
testing for women aged 25–64 years, as well as 
increasing the standard screening interval from 3 to 
5 years for women under 50 years of age. Our model 
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Figure 1 Overview of model representation of human papillomavirus (HPV) transmission and progression to cancer for each 
of eight HPV types (16, 18, 31, 33, 45, 51, 52, and 58).
has incorporated information on HPV acquisition, cervical disease 
progression, cancer incidence, and screening effectiveness.
METHOdS
A stochastic, individual-based simulation model (ie, a model which 
follows individual women in a population and has multiple random 
realizations) was developed to represent the natural history of 
cervical disease and potential impact of HPV- and cytology-based 
screening protocols. An overview of the model is shown in Figure 1; 
further technical details about the model structure and parame-
terisation are given in online supplementary Appendix A1-4. The 
model generates a cohort of women and simulates their lifetime 
history: (a) acquisition of HPV infection through partner acqui-
sition and sexual transmission as a necessary pre-condition for 
cervical pathogenesis, (b) natural progression of HPV infection, 
cervical intra-epithelial neoplasia (CIN) and cervical cancer, and (c) 
screening attendance, detection, and treatment of cervical abnor-
malities through cervical screening according to the algorithms in 
online supplementary Appendix Figures A6-7. Eight high-risk HPV 
types (16, 18, 31, 33, 45, 51, 52, and 58) are separately modeled. 
Women can acquire multiple HPV infections, possibly simultane-
ously with different strains, and each infection follows its own 
timeline to clearance or emergence of a pre-invasive cancer lesion, 
adenocarcinoma, or squamous cell carcinoma. HPV vaccination was 
not incorporated, as most women currently eligible for screening in 
England are not vaccinated. Clinical outcomes (screening results, 
colposcopies, treatment of pre-cancerous lesions, invasive cancer, 
and death) over the lifetime of the women are tracked and used to 
calculate the cost-effectiveness of each screening strategy.
Three alternative screening strategies were considered for 
women aged 25–64 years: (a) cytological screening with HPV 
testing to determine further management of cytological abnor-
mals ('primary cytology protocol'), with a 3-year (or 5-year for 
women over 50 years old) recall interval following a negative 
screen, which is the current screening practice in England; (b) HPV 
testing ('primary HPV protocol'), with cytological testing to deter-
mine further management of high-risk HPV positives, with a 3-year 
(or 5-year for women over 50 years old) recall interval following 
a negative primary screen; (c) HPV testing ('5-year primary HPV 
protocol') with an extended 5-year recall interval following a nega-
tive HPV screen, for all women regardless of age.
A cost-effectiveness analysis was conducted by comparing the 
incremental costs and quality-adjusted life-years (QALYs) over the 
lifetime of cohorts under different screening strategies. The refer-
ence case of the National Institute for Health and Care Excellence 
(NICE) was used.5 In particular, a healthcare provider perspective 
was used, costs were inflated to 2013/14 GBP (British Pound) using 
the Hospital and Community Health Services prices index, and 
discounting of 3.5% was used for both costs and QALYs. Probabi-
listic sensitivity analysis was conducted incorporating uncertainty 
in both epidemiologic and economic parameters.
The economic parameters used were estimated from the 
literature; they are summarized in Table  1, while their sources 
and derivation are explained in online supplementary appendix 
A5. Because quality of life weights for screening differed widely 
between studies, we conducted three separate analyses: (i) using 
weights from all preference-based utility studies identified,6–9 (ii) 
using weights from the study with the smallest screening-related 
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Table 1 Economic parameters used in the model
Parameter Cost (£) 95% range Source
Cost of screening
  Sample collection 15.31 (12.5 to 18.63) See online supplementary 
Appendix A5
  HPV test per sample* 9.75 (7.23 to 13.03) See online supplementary 
Appendix A5
  Cytology test per slide* 18.15 (14.95 to 22.02) See online supplementary 
Appendix A5
Cost of treatment of neoplasias and cancers
  Colposcopy 151.18 (124.18 to 184.08) 14
  Biopsy 79.84 (65.35 to 97.71) 15
  Excision 382.6 (313.89 to 468.41) 14
  Hysterectomy 2583.5 (2222.28 to 3039.77 14
  Chemotherapy 5089 (4203.03 to 6188.00 16
  Trachalectomy 5485.67 (4500.32 to 6646.50 16
  Radiotherapy 19 078 (15 709.73 to 23 126.39 16
   Stage 1 4619 (4105.25 to 5156.03 16 17
   Stage 2 20 704 (17 927.10 to 23 509.72 16 17
   Stage 3 20 387 (17 638.43 to 23 509.18 16 17
   Stage 4 17 320 (14 953.77 to 20 008.25 16 17
QALY loss per screening episode
  Cytology normal, HPV negative 0.0001 (0.00002 to 0.00023) 6–9
  Cytology low-grade, HPV negative, back to routine recall 0.0011 (0.00023 to 0.002)
  HPV positive, cytology normal, 12 month follow-up 
cytology
0.004 (0.00023 to 0.0089)
  Normal outcome at colposcopy 0.0147 (0.0015 to 0.04)
  CIN1 outcome at colposcopy 0.0618 (0.005 to 0.11)
  CIN2 outcome at colposcopy 0.0783 (0.003 to 0.13)
Quality of life weight for different cancer stages 18 19
  Stage I 0.295 (0.19 to 0.51)
  Stage II 0.385 (0.33 to 0.58)
  Stage III 0.44 (0.44 to 0.58)
  Stage IV 0.52 (0.4 to 0.64)
Quality of life weight for different cancer stages post-treatment
  Stage I 0.03 (0.01 to 0.27)
  Stage II 0.065 (0.02 to 0.32)
  Stage III 0.065 (0.02 to 0.32)
  Stage IV 0.205 (0.031 to 0.53)
*Includes consumables, equipment, staff time, and other overheads.
CIN, cervical intra-epithelial neoplasia; HPV, human papillomavirus; QOL, quality of life; QUALY, quality-adjusted life-years.
detriments,7 and (iii) using weights from the study with the highest 
screening-related detriments.10 This work was conducted by Public 
Health England in order to inform decision-making by the NHSCSP.
rESuLTS
HPV Testing
The model and best-fitting disease progression parameters are 
used to evaluate a change to the NHSCSP in England from primary 
cytology, the current protocol, to HPV testing, under the algorithm 
which is currently being implemented nationally.
Increased number of Tests Performed under HPV Testing
A summary of clinical outcomes under the HPV and cytology 
protocols is shown in Table 2 and figure 2. The annual number of 
primary screening tests is expected to increase by 5% under the 
standard HPV protocol from 3.14 to 3.31 million per annum; the 
largest increase is expected in women aged 25 to 35 years and 
 o
n
 2 M
ay 2019 by guest. Protected by copyright.
http://ijgc.bmj.com/
Int J G
ynecol Cancer: first published as 10.1136/ijgc-2018-000161 on 24 April 2019. Downloaded from 
4 Bains I, et al. Int J Gynecol Cancer 2019;0:1–7. doi:10.1136/ijgc-2018-000161
Original Article
Ta
b
le
 2
 
N
um
b
er
 o
f s
cr
ee
ni
ng
 t
es
ts
 a
nd
 c
ol
p
os
co
p
ie
s 
ca
rr
ie
d
 o
ut
 e
ac
h 
ye
ar
 (x
10
 0
00
) u
nd
er
 d
iff
er
en
t 
sc
re
en
in
g 
p
ro
to
co
ls
 (m
ea
n 
an
d
 9
5%
 C
I),
 a
ss
um
in
g 
20
13
 p
op
ul
at
io
n 
ag
e 
d
is
tr
ib
ut
io
n.
 B
or
d
er
lin
e 
in
d
ic
at
es
 r
es
ul
ts
 t
ha
t 
ca
nn
ot
 d
efi
ni
te
ly
 b
e 
cl
as
si
fie
d
 a
s 
ei
th
er
 n
or
m
al
 o
r 
ab
no
rm
al
.
S
cr
ee
ni
ng
 p
ar
am
et
er
s 
P
ri
m
ar
y 
cy
to
lo
g
y
P
ri
m
ar
y 
H
P
V
 (3
-y
ea
r 
re
ca
ll)
P
ri
m
ar
y 
H
P
V
 (5
-y
ea
r 
re
ca
ll)
M
ea
n
Lo
w
er
U
p
p
er
M
ea
n
Lo
w
er
U
p
p
er
M
ea
n
Lo
w
er
U
p
p
er
C
yt
ol
og
y 
te
st
s 
(x
10
 0
00
)
 
 A
ll
31
.4
6
30
.9
3
31
.9
6
3.
96
3.
72
3.
98
3.
25
2.
87
3.
24
 
 N
or
m
al
28
.6
4
28
.0
6
29
.3
1
2.
57
2.
27
2.
77
2.
06
1.
75
2.
06
 
 B
or
d
er
lin
e
1.
83
1.
39
2.
18
1.
08
0.
74
1.
28
0.
91
0.
67
0.
90
 
 M
ild
0.
72
0.
48
0.
97
0.
25
0.
16
0.
34
0.
21
0.
13
0.
21
 
 M
od
er
at
e
0.
17
0.
07
0.
28
0.
06
0.
03
0.
08
0.
05
0.
03
0.
05
 
 S
ev
er
e
0.
11
0.
02
0.
22
0.
01
0.
01
0.
02
0.
01
0.
00
0.
01
H
P
V
 t
es
ts
 (x
10
 0
00
)
 
 A
ll
2.
72
2.
21
3.
14
33
.1
6
32
.6
0
33
.5
9
26
.0
9
25
.5
2
26
.0
8
 
 H
P
V
 n
eg
at
iv
e
1.
58
1.
16
1.
96
28
.6
8
28
.3
0
29
.1
9
22
.4
3
21
.9
2
22
.4
3
 
 H
P
V
 p
os
iti
ve
1.
14
0.
90
1.
35
4.
48
4.
19
4.
50
0.
00
3.
22
3.
65
C
ol
p
os
co
p
ie
s 
(x
10
 0
00
)
 
 A
ll
1.
07
0.
84
1.
25
1.
47
1.
28
1.
55
1.
24
1.
04
1.
23
 
 N
or
m
al
0.
63
0.
47
0.
77
0.
78
0.
67
0.
83
0.
65
0.
54
0.
65
 
 C
IN
1
0.
24
0.
18
0.
28
0.
38
0.
32
0.
41
0.
32
0.
26
0.
32
 
 C
IN
2 
or
 w
or
se
0.
20
0.
15
0.
23
0.
32
0.
26
0.
35
0.
27
0.
22
0.
27
N
ew
 c
an
ce
r 
ca
se
s 
an
d
 d
ea
th
s
 
 C
as
es
21
18
14
75
28
69
18
28
10
16
27
38
19
99
13
56
30
22
 
 D
ea
th
s
52
0
36
4
70
4
46
1
32
5
75
2
47
5
33
7
77
7
S
cr
ee
ni
ng
 a
nd
 t
re
at
m
en
t 
co
st
s
 
 S
cr
ee
ni
ng
 (£
 m
ill
io
n)
13
4
12
2
14
5
12
0
11
2
13
1
98
91
10
7
 
 S
cr
ee
ni
ng
 a
nd
 t
re
at
m
en
t 
(£
 m
ill
io
n)
15
3
13
9
16
5
13
7
12
6
14
7
11
4
10
4
12
7
 
 D
is
co
un
te
d
 li
fe
tim
e 
co
st
s 
p
er
 w
om
en
 (£
)
16
0
14
6
17
2
14
5
13
4
15
7
12
1
10
8
13
1
D
is
co
un
te
d
 Q
A
LY
s 
lo
st
 p
er
 1
00
0 
w
om
en
 
 Li
fe
 y
ea
rs
 lo
st
 o
nl
y
15
.7
9.
2
23
.9
14
.6
7.
9
21
.2
15
.3
8.
5
22
.4
 
 Q
A
L Y
s:
 b
as
e 
ca
se
13
.6
10
.5
16
.5
16
12
.8
19
.8
14
.4
11
.3
17
.9
 
 Q
A
LY
s:
 m
in
im
um
 s
cr
ee
n 
Q
A
LY
 lo
ss
es
6
3.
7
8
5.
5
3.
3
7.
3
5.
2
3.
2
7.
6
 
 Q
A
LY
s:
 m
ax
im
um
 s
cr
ee
n 
Q
A
LY
 lo
ss
es
19
.5
15
.1
22
.5
22
.5
18
.4
26
.2
19
.9
16
.2
23
.7
C
IN
, c
er
vi
ca
l i
nt
ra
-e
p
ith
el
ia
l n
eo
p
la
si
a;
 H
P
V,
 h
um
an
 p
ap
ill
om
av
iru
s;
 Q
A
LY
, q
ua
lit
y-
ad
ju
st
ed
 li
fe
-y
ea
rs
.
 o
n
 2 M
ay 2019 by guest. Protected by copyright.
http://ijgc.bmj.com/
Int J G
ynecol Cancer: first published as 10.1136/ijgc-2018-000161 on 24 April 2019. Downloaded from 
5Bains I, et al. Int J Gynecol Cancer 2019;0:1–7. doi:10.1136/ijgc-2018-000161
Original Article
Figure 2 Number of women tested and predicted outcome 
under primary human papillomavirus (HPV) protocol and 
primary cytology protocol, assuming 2013 population age 
distribution in England.
Figure 3 Cervical cancer incidence predicted by model 
under primary cytology and primary human papillomavirus 
(HPV) protocols. Boxes represent the interquartile prediction 
interval.
represents an additional 73 000 tests on women that are followed 
after an HPV-positive result. A switch to the HPV protocol resulted in 
a reduction in the number of women undergoing cytological testing, 
from 3.14 to 0.38 million tests annually, while the proportion of 
women with positive cytology outcomes increased from 8.8% 
under cytology protocol to 35% under HPV protocol. A more detailed 
breakdown of number of tests and outcomes is shown for each 
screening strategy in the online supplementary Appendix.
Improved Efficiency of Screening under HPV Testing
The model predicts a 25% increase in women referred to colpos-
copy through the screening program, as the HPV protocol has lower 
positive predictive value than the cytology protocol. The model does 
not consider women referred to colposcopy following a clinical 
indication. The number of grade 2 or worse CIN cases identified 
annually is expected to increase by 44%; reflecting 22 000 addi-
tional cases detected per year through the screening program. The 
referral value, that is the number of women referred to colposcopy, 
by way of the screening program, per detection of one CIN2 or 
worse lesion, is projected to decrease from 2.6 to 2.3. In addition to 
the increased ‘efficiency’ of colposcopy, the total number of primary 
screens required to identify a single case of CIN2 or worse lesions 
is also predicted to drop from 158 using cytology protocol, to 104 
under HPV protocol.
reduced Cancer Incidence and Cancer-related deaths under 
Primary HPV Testing
Best-fitting model simulations cover a wide range of scenarios for 
cancer incidence when we combine cases of squamous cell carci-
noma and adenocarcinoma for HPV types 16,18, 31, 33, 51, 52, 
and 58 (Figure 3). The model predicts that a switch to HPV testing 
will result in a statistically significant decrease in the mean annual 
incidence of cervical cancer of 14.5%; equivalent to a reduction in 
290 cases per year in individuals aged 10 to 79 years (95% CI 195 
to 370). The number of cases detected in women aged 35+ years 
is expected to experience the largest drop, while the number of 
cases in women aged <30 years was not found to be significantly 
different between the two protocols. This corresponds to a mean 
reduction in cervical cancer-related deaths of 15.5%; 56 (range 
38−75) fewer deaths are predicted under the HPV testing protocol. 
In terms of the ‘efficiency of primary screening’, we find that the 
HPV protocol requires an additional 587 screens per cancer case 
avoided.
Cost Savings
A switch from cytology to the HPV protocol would lead to a total 
healthcare cost saving of £13 million (range £2.9−£22.8 million). 
The annual screening costs are expected to be £120.5 million. The 
discounted lifetime cost saving per women is estimated to be £14 
(range £1−£27).
QALY Changes
We do not find substantial changes in QALYs gained associated 
with a switch from cytology to a HPV protocol. The median (95% 
CI) QALYs gained over the lifetime of a woman in the model was 
(i) −0.0026 (-0.0064 to 0.013) when using all utility studies, (ii) 
0.0005 (−0.0013 to 0.0026)) when using the study with the 
smallest screening-related utility losses, and (iii) −0.0033 (−0.0004 
to 0.0064) when using the study with the largest.
Extended Screening Interval
We consider the impact of increasing the recall interval, following 
a negative HPV screen, to 5 years for all women regardless of age 
(5-year primary HPV protocol). This fixed interval compares to 
current practice whereby women aged under 50 years are recalled 
at 3-year intervals, and women aged over 50 years are recalled at 
5-year intervals. The model predicts that a switch from cytology to 
HPV testing with a 5-year interval for all women will lead to a 17% 
decrease in the number of primary tests carried out (Table 2). The 
model does not predict a significant difference in the number of 
colposcopies with a move from cytology to HPV with 5-year recall; 
however, the model predicts that more neoplasias will be detected 
per year. The increased ‘rate’ of detection per colposcopy under 
a 5-year protocol arises from the increased proportion of women 
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attending colposcopy following a moderate or severe cytological 
referral. Overall, the increased detection and subsequent treatment 
of pre-cancerous lesions results in a decrease in cancer incidence 
by 145 (range 82−246) cases per year under the 5-year HPV 
protocol, saves 47 (range 27−67) lives per year, and saves 0.0008 
discounted life-years per woman compared with cytology.
Moving from cytology to HPV testing, in combination with a 
regular 5-year screening interval, would lead to a substantial total 
healthcare cost saving of £33 million (range £23.7–£44.1 million). 
The annual screening costs are expected to be £97.7 million. The 
discounted lifetime cost saving per women is estimated to be £38 
(range £25–£49).
dISCuSSIOn
Our analysis suggests that a move from the current cytology to 
HPV screening without changing the recall interval will be both life-
saving and cost-saving, with no significant difference in net QALYs 
gained. Such a move is expected to: (i) increase the number of 
screening tests performed, (ii) increase the number of colposcopy 
referrals, (iii) increase the number of lesions identified and treated 
through colposcopy, and (iv) decrease cervical cancer incidence 
and mortality.
Even if the shift to HPV screening is accompanied by an increase 
in the recall interval to 5 years, this is still expected to reduce 
cancer incidence, mortality, and costs. However, the reduction in 
cervical cancer mortality will be smaller. Despite the smaller reduc-
tion in deaths, the reduction in the number of colposcopies required 
means that a 5-year HPV protocol is more favorable in terms of net 
QALYs than a 3-year HPV protocol. Further reductions in colpos-
copies may be achievable by using alternative triage technologies 
(such as partial or full genotyping), although this was not modeled.
The cost-effectiveness of HPV testing in England was previously 
estimated using results from the ARTISTIC trial of HPV testing.11 
This analysis also found HPV testing to be cost-effective and 
life-saving if accompanied by an increase in screening intervals 
to at least 5 years, but reached divergent outcomes in terms of 
the impact on QALYs depending on the assumptions made. Our 
analysis verifies and updates these results by using more recent 
screening and sexual behavior data, an independent model, and 
scenarios of direct interest to the National Screening Committee. 
A recent systematic review12 found that the majority of relevant 
model-based studies found HPV testing to be more cost-effective 
than cytology, which is in line with our results.
While the model reproduces HPV prevalence and cervical cancer 
incidence in the English population well, it does not capture a 
second peak in cancer incidence seen in women aged over 70 
years. Cancers in older women are more likely to arise from high-
risk HPV types rarely seen in cervical cancer, and not included in 
the model. Joste et al13 showed that 100% of cancers in women 
aged under 30 years were attributable to modeled HPV types (16, 
18, 31, 33, 45, 51, 52, and 58); however, this dropped to 75% in 
women aged over 40 years. Hence we may slightly underestimate 
the benefit of HPV testing in older women, since commercially 
available tests, such as the commonly used Hybrid Capture 2 assay, 
will also detect non-modeled types such as 35, 39, 56, 59, and 68. 
Another explanation for missing the second cancer peak is that it 
represents the effect of both cohort differences and age-related 
changes. The model calibration assumes that all women undergo 
screening according the current protocol from age 25 to 65 years. 
However, the NHSCSP began in 1988 so women aged 70+ years in 
the 2012 dataset would only have benefited from screening from 
age 45 years onwards. Model projections give a large uncertainty 
range around cancer incidence, representing the combined uncer-
tainty from 16 distinct cancer-causing processes (eight HPV types 
leading to either squamous cell carcinomas or adenocarcinomas). 
Many of these HPV types are only rarely associated with cervical 
cancer in English women, so there are sparse data to constrain the 
underlying parameters.
We used costs from historical economic analyses of screening 
in England, inflated to 2014 values.11 The limitations of inflating 
historical costs are that we do not necessarily capture reduction in 
technology costs over time. Economies of scale also suggest that a 
switch to primary screening is likely to result in a reduction in the 
cost per HPV test. Overall, this will lead to further cost savings asso-
ciated with a switch to HPV testing. Work on the detailed design and 
implementation of HPV testing is ongoing within the NHSCSP: this 
work includes developing appropriate education for professionals 
and information for patients.
There are large discrepancies in the literature for the utility detri-
ments associated with cervical screening (particularly HPV-related 
screening) depending on the methodology used for eliciting util-
ities. We used sensitivity analyses to capture the extreme values 
reported in the literature; these suggest that the choice of utility 
values to use can determine whether an intervention is cost-effec-
tive in terms of its cost per QALY gained. This highlights the need 
for deeper understanding the QOL impact of screening, in order 
to appropriately judge what increase in colposcopies and pre-can-
cerous lesion treatments we are willing to accept in exchange for 
reductions in cervical cancer incidence and deaths.
The current analysis is based on a static model of infection, since 
changes in screening are unlikely to have a major effect on the rate 
at which women are infected with HPV. However, it is important to 
consider the implications of HPV vaccination (introduced in England 
in 2008) on HPV acquisition as vaccinated cohorts approach 
screening age. Further work needs to focus on identifying optimal 
screening strategies among both vaccinated and unvaccinated 
women among the age cohorts who were at the right age to be part 
of the national vaccination programme.
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